D. Western Therapeutics Institute Past Earnings Performance
Past criteria checks 0/6
D. Western Therapeutics Institute's earnings have been declining at an average annual rate of -21.1%, while the Biotechs industry saw earnings growing at 23% annually. Revenues have been declining at an average rate of 1.1% per year.
Key information
-21.1%
Earnings growth rate
-15.9%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -1.1% |
| Return on equity | -64.7% |
| Net Margin | -189.7% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How D. Western Therapeutics Institute makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 428 | -812 | 258 | 930 |
| 30 Sep 23 | 452 | -646 | 263 | 663 |
| 30 Jun 23 | 425 | -566 | 262 | 564 |
| 31 Mar 23 | 429 | -505 | 260 | 507 |
| 31 Dec 22 | 448 | -429 | 255 | 469 |
| 30 Sep 22 | 408 | -273 | 251 | 439 |
| 30 Jun 22 | 423 | -176 | 247 | 363 |
| 31 Mar 22 | 434 | -128 | 242 | 326 |
| 31 Dec 21 | 414 | -148 | 248 | 316 |
| 30 Sep 21 | 430 | -227 | 248 | 394 |
| 30 Jun 21 | 405 | -262 | 261 | 379 |
| 31 Mar 21 | 370 | -274 | 264 | 354 |
| 31 Dec 20 | 355 | -276 | 253 | 350 |
| 30 Sep 20 | 369 | -136 | 232 | 252 |
| 30 Jun 20 | 368 | -98 | 202 | 251 |
| 31 Mar 20 | 379 | -62 | 184 | 247 |
| 31 Dec 19 | 580 | 133 | 187 | 249 |
| 30 Sep 19 | 538 | -61 | 208 | 388 |
| 30 Jun 19 | 537 | -248 | 231 | 566 |
| 31 Mar 19 | 514 | -412 | 263 | 683 |
| 31 Dec 18 | 292 | -748 | 268 | 795 |
| 30 Sep 18 | 267 | -798 | 269 | 823 |
| 30 Jun 18 | 293 | -605 | 269 | 753 |
| 31 Mar 18 | 279 | -1,578 | 263 | 675 |
| 31 Dec 17 | 254 | -1,563 | 276 | 603 |
| 30 Sep 17 | 239 | -1,398 | 276 | 459 |
| 30 Jun 17 | 151 | -1,464 | 276 | 338 |
| 31 Mar 17 | 126 | -385 | 266 | 284 |
| 31 Dec 16 | 168 | -253 | 260 | 226 |
| 31 Dec 15 | 61 | -296 | 195 | 143 |
Quality Earnings: 4576 is currently unprofitable.
Growing Profit Margin: 4576 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4576 is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare 4576's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4576 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: 4576 has a negative Return on Equity (-64.66%), as it is currently unprofitable.